Transient Abnormal Myelopoiesis: A Varied Spectrum of Clinical Presentation
暂无分享,去创建一个
[1] J. Vergilio,et al. Transient abnormal myelopoiesis in neonates: GATA get the diagnosis. , 2014, Archives of pathology & laboratory medicine.
[2] P. Heimann,et al. Transient leukemia in a newborn without Down syndrome: case report and review of the literature , 2014, European Journal of Pediatrics.
[3] Y. Hayashi,et al. Liver disease is frequently observed in Down syndrome patients with transient abnormal myelopoiesis , 2014, International Journal of Hematology.
[4] F. Smith,et al. Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder , 2012, British journal of haematology.
[5] R. Arceci,et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. , 2011, Blood.
[6] A. Tragiannidis,et al. Transient myeloproliferative disorder in a newborn with down syndrome treated with rasburicase for the risk of development of tumor lysis syndrome: A case report , 2011, Journal of medical case reports.
[7] S. Mahmood,et al. Clinicopathological features of transient myeloproliferative syndrome and congenital leukaemia. , 2010, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.
[8] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[9] D. Reinhardt,et al. Immunophenotype of Down Syndrome Acute Myeloid Leukemia and Transient Myeloproliferative Disease Differs Significantly from Other Diseases with Morphologically Identical or Similar Blasts , 2005, Klinische Padiatrie.
[10] A. Zipursky,et al. Telomerase and the Benign and Malignant Megakaryoblastic Leukemias of Down Syndrome , 2002, Journal of pediatric hematology/oncology.
[11] M. Digilio,et al. Health Supervision for Children With Down Syndrome , 1994, Pediatric Clinical Practice Guidelines & Policies.